- Home
- RGNX vs VSTM Comparison
RGNX vs VSTM Comparison
Compare RGNX & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGNX
- VSTM
- Stock Information
- Founded
- RGNX 2008
- VSTM 2010
- Country
- RGNX United States
- VSTM United States
- Employees
- RGNX N/A
- VSTM N/A
- Industry
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- RGNX Health Care
- VSTM Health Care
- Exchange
- RGNX Nasdaq
- VSTM Nasdaq
- Market Cap
- RGNX 661.2M
- VSTM 581.6M
- IPO Year
- RGNX 2015
- VSTM 2012
- Fundamental
- Price
- RGNX $12.77
- VSTM $9.45
- Analyst Decision
- RGNX Strong Buy
- VSTM Strong Buy
- Analyst Count
- RGNX 7
- VSTM 9
- Target Price
- RGNX $30.00
- VSTM $13.38
- AVG Volume (30 Days)
- RGNX 601.4K
- VSTM 2.4M
- Earning Date
- RGNX 11-06-2025
- VSTM 11-04-2025
- Dividend Yield
- RGNX N/A
- VSTM N/A
- EPS Growth
- RGNX N/A
- VSTM N/A
- EPS
- RGNX N/A
- VSTM N/A
- Revenue
- RGNX $155,782,000.00
- VSTM $2,137,000.00
- Revenue This Year
- RGNX $198.02
- VSTM $79.32
- Revenue Next Year
- RGNX $2.67
- VSTM $413.52
- P/E Ratio
- RGNX N/A
- VSTM N/A
- Revenue Growth
- RGNX 74.95
- VSTM N/A
- 52 Week Low
- RGNX $5.04
- VSTM $3.46
- 52 Week High
- RGNX $13.93
- VSTM $11.25
- Technical
- Relative Strength Index (RSI)
- RGNX 58.75
- VSTM 59.00
- Support Level
- RGNX $12.66
- VSTM $7.60
- Resistance Level
- RGNX $13.93
- VSTM $9.16
- Average True Range (ATR)
- RGNX 0.72
- VSTM 0.64
- MACD
- RGNX -0.04
- VSTM 0.07
- Stochastic Oscillator
- RGNX 61.82
- VSTM 84.59
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.